Characterized by high incidence and long treatment durations, the breast cancer market represents a great commercial opportunity for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio/Verzenios/Virginio) are creating new dynamics in the metastatic HR-positive/HER2-negative treatment practice. In HER2-positive breast cancer, emerging HER2-targeting drugs in development are forecast to enter the market, while current HER2-targeting agents will see their sales change as a result of competition, label expansions, biosimilars entry, and new trials leading to changes in treatment guidelines. Furthermore, the approval of PARP inhibitors (AstraZeneca’s Lynparza and Pfizer’s Talzenna), PD-1-targeting agents (Roche/Genentech/Chugai’s Tecentriq), and PI3K inhibitors (Novartis’s Piqray), as well as anticipated entry of agents within these drug classes will provide more diverse and much needed treatment options, especially for triple-negative breast cancer.

Questions answered

  • What is the size of the drug-treatable breast cancer population, and how will drug-treatment rates change over time?
  • What is the expected market impact of recent drug approvals, such as the CDK4/6 inhibitors, immune checkpoint inhibitors, PARP  inhibitors, and PI3K inhibitors in the various subpopulations of breast cancer?
  • What are the most promising agents in the pipeline, and how will they shape the future of the breast cancer market?
  • What are the drivers and constraints in the breast cancer market, and how will the market evolve over the forecast period?

Contents Highlights

Geographies: United States, EU5, Japan

Primary Research: 19 country-specific interviews with thought-leading medical oncologists supported by survey data collected for this and other DRG research

Epidemiology: Incidence of breast cancer by country, segmented by HR and HER2 status, staging, and line of therapy

Forecast: 10-year, annualized, drug-level sales and patient share of key breast cancer therapies through 2028, segmented by brands/generics and market-relevant drug-treatable populations

 Emerging Therapies: Phase III/PR: 15 drugs; coverage of select Phase I and II products

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Findings
      • Breast Cancer - Key Findings - September 2019
    • Key Updates
      • September 2019
      • June 2019
      • March 2019
      • December 2018
      • October 2018
    • Market Outlook
      • Key Findings
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Breast Cancer?
        • What Factors Are Constraining the Market for Breast Cancer?
      • Segment-Specific Trends
        • Adjuvant and Neoadjuvant Market
        • First-Line Market
        • Second- and Subsequent-Line Market
    • Forecast
      • Market Forecast Downloads
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
      • Disease Pathophysiology
        • Prognostic Biomarkers
        • Patterns of Metastasis
      • Staging and Classification
        • Staging of Breast Cancer
      • Prognostic Gene Expression Signatures
        • Oncotype Dx
        • MammaPrint
        • The Quest H:I Ratio Test
      • Key Pathways and Drug Targets
        • Key Pathways and Drug Targets for Breast Cancer
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • Molecular Subtype
        • Stage at Diagnosis
        • Menopausal Status
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • HER2-Targeted Agents
        • CDK4/6 Inhibitors
        • mTOR Pathway Inhibitors
        • Angiogenesis Inhibitors
        • Cytotoxic Agents
        • SERDs
        • PARP Inhibitors
        • Immune Checkpoint Inhibitors
        • PI3K Inhibitors
      • Medical Practice
        • Neoadjuvant Treatment of Stage II/III Breast Cancer
        • Adjuvant Treatment of Stage I-III Breast Cancer
        • First-Line Treatment of Advanced/Metastatic Breast Cancer
        • Second- and Subsequent-Line Treatment of Advanced/Metastatic Breast Cancer
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Breast Cancer
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • PARP Inhibitors
        • PI3K/AKT/mTOR Pathway Inhibitors
        • Immune Checkpoint Inhibitors
        • HER2/EGFR-Targeting Agents
        • Cytotoxic Agents
        • HDAC Inhibitors
        • Cancer Vaccines
        • CXCR4 Inhibitors
        • SERDs
      • Early-Phase Pipeline Analysis
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Breast Cancer Bibliography

Author(s): Paul Wilcock. PhD; Alexandre Vo Dupuy (PhamD, MSc)

Since October 2015, Dr. Wilcock has been a Business Insights Analyst in the oncology team at Decision Resources Group. He has experience in various indications including metastatic malignant melanoma and renal cell carcinoma, and will have a major focus on gastric cancer going forward. Previously, Dr. Wilcock was a Research Funding Manager at Cancer Research UK, where he developed a deep understanding of drug discovery, predominantly in the academic setting. He gained his doctorate from the University of Manchester where he utilized Systems Biology to explore the role of cell signaling and hypoxia in oral cancer.

Alexandre joined Decision Resources Group in 2017 as an Associate Epidemiologist. He holds a PharmD from Paris Descartes University as well as a Master in pharmacoepidemiology from the University of Bordeaux.   Prior to joining Decision Resources Group, he worked within the fields of Consulting and Real World Evidence ,   and as an intern within the Global Epidemiology department of   one of the top pharmaceutical company . As an associate epidemiologist, Alexandre works across multiple disease areas estimating and forecasting incidence and prevalence, with a focus on cancer epidemiology.


Related Reports

Breast Cancer | Unmet Need | Detailed, Expanded Analysis: Advanced/Metastatic Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is a patient population with high unmet need given the poor outcomes associated with current treatment...

View Details

Breast Cancer | Access & Reimbursement | Detailed, Expanded Analysis - Optimizing Market Access Amid an Evolving Landscape for HR+/HER2- Therapies (EU)

MARKET OUTLOOK The lucrative HR-positive, HER2-negative breast cancer market in Europe is fast-moving and competitive. CDK4/6 inhibitors Ibrance (Pfizer), Kisqali (Novar...

View Details

Breast Cancer | Epidemiology | Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key breast cancer patient popu...

View Details

Breast Cancer | Access & Reimbursement | Detailed, Expanded Analysis: Special Focus on Breast Cancer: Use of Clinical Pathways (US)

Market Outlook Clinical pathways, which establish optimal treatment protocols for specific patient populations based on the best evidence, have become increasingly preva...

View Details